Neos Therapeutics, Inc., a Dallas-Fort Worth based pharmaceutical company with a late-stage pipeline of several candidates to treat Attention-Deficit Hyperactivity Disorder (ADHD), recently announced the appointment of Thomas P. McDonnell as its Chief Commercial Officer, effective immediately.
Before joining Neos, McDonnell spent 10 years with Shire as the Vice President of the US Marketing in the Neuroscience Business Unit between December 2013 and March 2015. He guided the US Product Strategy Team responsible for the commercialization of Intuniv and Vyvanse to enter the ADHD market. Between August 2012 and November 2013, he led the product strategy team for the marketing and clinical development of Vyvanse in Major Depressive Disorder and Binge Eating Disorder and was Vice President, General Manager of Adult Psychiatry.
In addition, he also held other commercial and marketing positions at Shire, including Senior Director, General Manager for Equasym XL, Senior Director of Marketing for Intuniv, Director of Marketing for Vyvanse, and Senior Product Manager for Adderall XR.
Before being at Shire, between 1997 and 2005 McDonnell held various sales, sales management and marketing positions at Abbott Laboratories and Knoll Pharmaceuticals. He received his Marketing B.A. from Muhlenberg College.
“I am very excited to welcome Tom to the Neos team. His wealth of experience in commercializing and marketing innovative therapeutic products for the treatment of ADHD, combined with his strong leadership and strategic planning skills, strengthen the management team at a key time in our development as a company. We look forward to his contributions as we prepare for the potential launches of our methylphenidate XR-ODT, NT-0102, amphetamine XR-ODT, NT-0202, and amphetamine XR Liquid Suspension, NT-0201, ADHD medications based on Neos’ patented XR-ODT or XR Liquid Suspension technology,” stated Vipin K. Garg, Neos’ President and Chief Executive Officer.
Neos Therapeutics, Inc. also recently announced a New Drug Application submission to the US Food and Drug Administration for its methylphenidate XR-ODT pipeline drug, NT-0102 — indicated to treat ADHD, and formulated using Neos’ proprietary XR-ODT technology.